Postoperative irinotecan in resected stage II-III rectal cancer: Final analysis of the French R98 Intergroup trial

Annals of Oncology

Volumn 26, Issue 6, 2015, Pages 1208-1215

  Delbaldo, Catherine ^a   Ychou, M ^b   Zawadi, A ^c   Douillard, J Y ^d   Andre T ^e   Guerin Meyer, V ^f   Rougier, P ^g   Dupuis, O ^h   Faroux, R ^c   Jouhaud, A ⁱ   Quinaux, E ^j   Buyse, M ^j   Piedbois, P ^k  

^a GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^b CENTRE VAL D AURELLE   (France)

^c Radiotherapy Unit Departemental Hospital Center   (France)

^d René Gauducheau Center   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f CENTRE PAUL PAPIN   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h CENTRE JEAN BERNARD   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^k Paul Strauss Centre   (France)

more..

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Irinotecan; Phase III; Rectal cancer; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADULT; AGED; ALOPECIA; ANTICHOLINERGIC SYNDROME; ARTICLE; BLEEDING; CANCER STAGING; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; EXPERIMENTAL DESIGN; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; REPEATED DRUG DOSE; SKIN TOXICITY; THROMBOCYTE COUNT; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VOMITING; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE COURSE; EARLY TERMINATION OF CLINICAL TRIAL; FRANCE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RECTAL NEOPLASMS; RISK FACTOR; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FLUOROURACIL; FRANCE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; RECTAL NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938056526     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv135     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005; 16: 481-488.
3. Kerr J, Engel J, Eckel R et al. Survival for rectal cancer patients and international comparisons. Ann Oncol 2005; 16: 664-672.
4. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27(19): 3109-3116.
5. Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 2012; 4: 75.
6. Rousseau B, Chibaudel B, Bachet JB et al. Stage II and stage III colon cancer:treatment advances and future directions. Cancer J 2010; 16: 202-209.
7. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 2001; 358: 1291-1304.
8. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Eng J Med 2001; 345: 638-646.
9. Gérard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625.
10. Collette L, Bosset JF, den Dulk M et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25: 4379-4386.
11. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. NEJM 2006; 355: 1114-1123.
12. Dubé S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma. Results of a meta-analysis. Dis Colon Rectum 1997; 40: 35-41.
13. Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21:2896-2903.
14. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
15. Conférence de consensus: le choix des thérapeutiques du cancer du rectum (paris 1er et 2 décembre 1994). La lettre du Cancérologue IV 1995; 12-17.
16. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and lowdose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250.
17. De Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly lowdose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815.
18. Sargent DJ, Patiyil S, Yothers G et al. Endpoints for colon cancer adjuvant trials:observations and recommendations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2007; 25: 4569-4574.
19. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300.
20. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP Protocol R-01. J Natl Cancer Inst 1988; 80: 21-29.
21. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715.
22. Sakamoto J, Ohashi Y, Hamada C et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum; Meta-Analysis Group in Cancer. J Clin Oncol 2004; 22(3): 484-489.
23. Petersen SH, Harling H, Kirkeby LT et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012; 14: 3.
24. Bosset JF, Calais G, Mineur L et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014; 15(2): 184-190.
25. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
26. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
27. Yothers G, O'Connell MJ, Allegra CJ et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29(28): 3768-3774.
28. Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471.
29. Ychou M, Raoul JL, Douillard JY et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009; 20(4): 674-680.
30. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27(19):3117-3125.
31. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25(23):3456-3461.
32. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
33. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
34. Hong YS, Nam BH, Kim KP et al. Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy:updated results of 3-year disease-free survival from a randomized phase II study (The ADORE). J Clin Oncol 2014; 32(5s suppl): abstr 3502.
35. Rodel C, Liersch T, Fietkau R et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol 2014; 32(5s suppl): abstr 3500.
36. Schmoll HJ, Haustermans K, Price TJ et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. J Clin Oncol 2014; 32(5s suppl): abstr 3501.